A Phase II Study of Atorvastatin (aka Lipitor) is now recruiting people across the US who have been diagnosed with Clinically Isolated Syndrome (CIS) and are at Risk for Multiple Sclerosis.
The definition of CIS, eligibility criteria and locations of centers recruiting people may be found here.
The study hypothesis states:
Early intervention with atorvastatin in patients with CIS will result in a state of immunological tolerance.
The eventual findings should be interesting given the front page story.
Take care everyone.